Causes and treatment of bone pain of malignant origin

Drugs

Volumn 51, Issue 3, 1996, Pages 383-398

  Thürlimann, Beat ^a,b   De Stoutz, Noémi D ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; INTERFERON; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; VINCA ALKALOID;

ANALGESIA; BONE ATROPHY; BONE MARROW; BONE PAIN; CANCER; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG CHOICE; EPIDURAL ANESTHESIA; FRACTURE; GASTROINTESTINAL HEMORRHAGE; HUMAN; IMMOBILIZATION; MEDICAL ASSESSMENT; NERVE BLOCK; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; RADIOGRAPHY; REVIEW; SCINTISCANNING; SPINAL ANESTHESIA; SPINAL CORD COMPRESSION; TUMOR GROWTH;

EID: 0029925697     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651030-00004     Document Type: Review

References (72)

1. Galasko CSB. Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop 1982; 169: 20-7
2. Nolkins H. Tumorhandbuch: Pathologie und Klinik der menschlichen Tumoren. 2. Auflage, Band 3, Kapitel 22, Munich: Urban und Schwarzenberg, 1987
3. Haq M, Goltzman D, Tremblay G, et al. Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells. Cancer Res 1992; 52: 4613-9
4. Nakai M, Mundy GR, Williams PJ, et al. A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice. Cancer Res 1992; 52: 5395-9
5. Powell GJ, Southby J, Danks JA, et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 1991; 51: 3059-61
6. Kostenuik PJ, Singh G, Suyama KL, et al. Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walder 256 cancer cells in bone. Clin Exp Metastasis 1992; 10: 411-8
7. Body JJ, Delmas PD. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 1992; 74: 471-5
8. Coleman RE, Houston S, James I, et al. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. Br J Cancer 1992; 65: 766-8
9. Boehringer Mannheim. European Multicenter Study. Data on file
10. Hanks GW, Portenoy RK, MacDonald RN, et al. Difficult pain problems. In: Doyle D, Hanks GWS, McDonald RN, editors. Oxford textbook of palliative medicine. Oxford: Oxford University Press, 1993
11. Bruera E. Bone pain due to cancer: 'why do we care' pain + symptom control. Psychiatric issues and ethical dilemmas in the care of patients with cancer: syllabus of the postgraduate course. New York: Memorial Sloan Kettering Cancer Center, 1992; 179-294
12. Bonica JJ. Control of bone cancer pain. In: Garattine S, editor. Bone resorption, metastases and diphosphonates. New York: Raven Press, 1985: 137-80
13. Galasko CSB. Orthopedic principles and management. In: Doyle D, Hanks GWS, McDonald RN, editors. Oxford textbook of palliative medicine. Oxford: Oxford University Press, 1993
14. Bruera E, Ripamonti C. Alternative routes of administration of opioids for the management of cancer pain. In: R. Patt, editor. Cancer pain. Philadelphia (PA): JB Lippincott Co., 1992: 161-84
15. Portenoy RK, Galer BS, Salamon O, et al. Identification of epidural neoplasms - radiography and bone scintigraphy in the symptomatic and asymptomatic spine. Cancer 1989; 64 (1): 2207-13
16. Keating MS, Estey E, Kantarjian H. Acute Leukemia. In: de Vita VT, Hellman S, Rosenberg SA, editors. Cancer: priciples and practice of oncology. 4th ed. Philadelphia (PA): JB Lippincott Co., 1993: 1941-2
17. Chigira M, Watanabi H, Maehara S, et al. Pain and internal hypertension in bone lesions. Acta Orthop Scand 1984; 55 (3): 375-7
18. Haynes RC. Adrenocortical steroids. In: Goodman Gilman A, Rann TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990: 1436-58
19. Foley K. Pain assessment and cancer pain syndromes. In: Doyle D, Hanks GWS, MacDonald R, editors. Oxford textbook of palliative medicine. Oxford: Oxford University Press, 1993
20. Chapman CR, Casey KL, Dubner R, et al. Pain measurement: an overview. Pain 1985; 22: 1-31
21. Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain 1986; 17: 117-26
22. Senn HJ. Schmerzerfassung und -Dokumentation bei Tumorkranken: Theorie und Realität. Schweiz Rundschau Med Prax 1993; 82 (9): 244-50
23. Cancer pain relief and palliative care: report of a WHO Expert Committee. WHO Technical Report Series, No. 804. Geneva: World Health Organization, 1990
24. Malawer MM, Delaney TF. Treatment of metastatic cancer to bone. In: de Vita VT, Hellman S, Rosenberg SA, editors. Cancer: priciples and practice of oncology. 4th ed. Philadelphia (PA): JB Lippincott Co., 1993; 2225-38
25. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic metastases: final results of the study by the Radiation Therapy Oncology Group. Cancer 1982; 50: 893-9
26. Madsen EL. Painful bone metastases: efficacy of radiotherapy assessed by the patients. A randomized trial comparing 4Gy × 6 versus 10Gy × 2. Int J Radiat Oncol Biol Phys 1983; 9: 1775
27. Blitzer T. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastases. Cancer 1985; 55: 1468-73
28. Ashby M. The role of radiotherapy in palliative care. J Pain Symptom Manage 1991; 6 (6): 380-8
29. Teoh N. Curbing cancer: relieving cancer pain. Int Pharm J 1990; 4 (3): 115-7
30. Portenoy RK. Cancer pain management. Sem Oncol 1993; 20 (2 Suppl. 1): 19-35
31. Insel PA. Analgesic-antipyretics and antiinflammatory agents: drugs employed in the treatment of rheumatoid arthritis and gout. In: Goodman Gilman A, Rann TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990; 638-81
32. Perl ER. Sensitization of nociceptors and its relation to sensation. In: Bonica JJ, Albe-Rersard DR, editors. Advances in pain research and therapy. Vol. 1. New York: Raven Press, 1976; 17-34
33. Medical Research Council (MRC). Choosing a non-steroidal antiinflammatory drug. Int Pharm J 1995; 9: 59-61
34. Rodriguez LAG, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal antiinflammatory drugs. Lancet 1994; 343: 739-72
35. Graham DY, Agrawal NM, Roth S. Prevention of non-steroidal antiinflammatory drug induced gastric ulceration with misoprostol: multicenter, double-blind placebo controlled trial. Lancet 1988; 2: 1277-80
36. Fainsinger RL, Miller MJ, Bruera E. Morphine intoxication during acute reversible renal insufficiency. J Palliat Care 1990; 8 (2): 52-3
37. Stiefel F, Morant R. Morphine intoxication during acute reversible renal insufficiency. J Palliat Care 1991; 7 (4): 45-7
38. Galer BS, Coyle N, Pasternak GW, et al. Individual variability in the response to different opioids: report of five cases. Pain 1992; 49: 87-91
39. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995; 10: 378-84
40. Bruera E, Macmillan K, Houson J, et al. The Edmonton staging system for cancer pain: preliminary report. Pain 1989; 37: 203-9
41. Portenoy RK, Hagen N. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41: 273-83
42. Bruera E, Fainsinger R, MacEachern T, et al. The use of methylphenidate in patients with incident cancer pain receiving regular opiates: a preliminary report. Pain 1992, 50: 75-7
43. Bruera E, Brenneis C, Paterson AH, et al. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Sympt Manage 1989; 4 (1): 3-6
44. Bruera E, Roca E, Cecaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69 (7/8): 751-4
45. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Int Med 1994; 236: 619-32
46. Griffin MR, Piper JM, Dougherty JR, et al. Non-steroidal antiinflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257-63
47. Daley-Yates PT, Dodwell DJ, Pongchaidecha M, et al. The clearance and biovailability of pamidronate in patients with breast cancer and bone metastases. Calcif Tissue Int 1991; 49: 433-5
48. Belch AR, Bergsagel ED, Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991; 9: 1397-402
49. Paterson AHG, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65
50. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 491-8
51. Lahtinen R, Laakso M, Palva I, et al. Finnish Leukaemia Group: randomized placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049-52
52. Elomaa I, Blomqvist C, Porkka L, et al. Diphosphonates for osteolytic metastases. Lancet 1985; 1: 1156-7
53. Delmas PD, Charhon S, Chapuy MC, et al. Long term effects of dichloromethylene diphosphonate on skeletal lesions in multiple myeloma. Metab Bone Dis Rel Res 1982; 4: 163-8
54. Kylmala T, Tamella T, Ristelli L, et al. Evaluation of oral clodronate on skeletal metastases with type I collagen metabolites: a controlled trial of the Finnish prostate cancer group. Eur J Cancer 1993; 29A: 821-5
55. Heim ME, Clemens MR, Queisser W, et al. Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment: a multicentre study. Onkologie 1995; 18: 439-48
56. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastastic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 1995; 9 (13): 2427-30
57. Ernst DS, MacDonald RN, Paterson AHG, et al. A double blind crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage 1992; 7: 4-11
58. Coleman RE, Woll PJ, Miles M, et al. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD). Br J Cancer 1988; 58: 621-5
59. Morton AR, Cantrill JA, Pillai GV, et al. Sclerosis of lytic bone metastases after disodium aminohydrocypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ 1988; 197: 772-3
60. Thiébaud D, Leyvraz S, De Fliedner V, et al. Treatment of hone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 1991; 27: 37-41
61. Lipton A, Glover D, Harvey H, et al. Disodium pamidronate (APD) - a dose-seeking study in patients with breast cancer and prostate cancer: preliminary report. In: Bijvoet OLM, Lipton A, editors. Osteoclast inhibition in the managemant of malignancy-related bone disorders. Lewingston (NY): Hogrefe and Huber, 1991: 33-44
62. Thürlimann B, Morant R, Jungi WF, et al. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. Support Care Cancer 1994; 2: 61-5
63. Thürlimann B. Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects? Ann Oncology 1994; 5 Suppl. 7: 45-7
64. Thürlimann B, Weisser F, Radziwill A, et al. Pamidronate in patients with malignant osteolytic bone disease and pain: a prospective randomised dose-finding study [abstract no. 1488]. In: Perrey MC, editor. American Society of Clinical Oncology Proceedings; 1993 Orlando (FL). W.B. Saunders Co., 1993; 12: 4320
65. Body JJ. Medical treatment of tumor-induced hypercalcemia and tumor induced osteolysis: challenges for future research. Support Care Cancer 1993; 1: 26-33
66. Berenson J, Lichtenstein A, Porter L, et al. Pamidronate disodium reduces the occurrence of skeletal related events in advanced multiple myeloma [abstract no. 1529]. Blood 1994; 84 (10 Suppl. 1): 386A
67. Conte PF, Gianesse PG, Latreille J, et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomised multicenter phase-III trial. Ann Oncol 1994; 5 Suppl. 7: 41-4
68. Sydow FW. Regionalanästhesiologische Methoden in der Schmerztherapie. In: Zenz M, Jurna I, editors. Lehrbuch der Schmerztherapien: Grundlagen, Theorie und Praxis für Ausund Weiterbildung. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1993: 229-38
69. Winkelmüller W. Neurochirurgische Methoden. In: Zenz M, Jurna I, editors. Lehrbuch der Schmerztherapie: Grundlagen, Theorie und Praxis für Aus- und Weiterbildung. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1993; 209-19
70. Higinbotham NL, Marcove RC. The management of pathological fractures. J Trauma 165; 5: 792-8
71. Gainor WJ, Buchen P. Fracture healing in metastatic bone disease. Clin Orthop 1983; 178: 297-302
72. Galasko CSB. The management of the skeletal metastases. J R Coll Surg Edinb 1980; 25: 143-61